Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Abivax SA (Abivax) is a biopharmaceutical company that primarily focuses on the discovery and development of novel treatments for chronic inflammatory diseases. The company offers product obefazimod, developed for the treatment of inflammatory diseases, starting with ulcerative colitis. Its pipeline products include obefazimod, ABX464 and ABX196. The company's ABX196 treats hepatocellular carcinoma, obefazimod for Crohn's disease and others. Abivax's products are aimed at patients suffering from chronic inflammatory conditions of the gastrointestinal tract, such as ulcerative colitis and Crohn's disease. The company also develops various technology platforms including an antiviral platform, immune enhancer platform and polyclonal antibody platform. It operates in France. Abivax is headquartered in Paris, France.
Headquarters
France
Address
7-11 Boulevard Haussmann, Paris, Ile-de-France, 75009
Website
www.abivax.com
Telephone
330 153 830963
No of Employees
68
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ABVX (EPA)
EPS
XYZ
Net Income (2024)
XYZ
-90.7%
(2024 vs 2023)
Market Cap*
$10.8B
Net Profit Margin (0 vs)
XYZ
0.0%
(2024 vs 2023)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline: |
| Obefazimod |
| ABX464 |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Corporate Changes/Expansions | In October, the company closed its initial public offering on the Nasdaq Global Market. |
| 2022 | Contracts/Agreements | In December, the company received US Food and Drug Administration agreement on the initial pediatric study plan for the development of obefazimod in ulcerative colitis in children. |
| 2017 | Contracts/Agreements | In September, Abivax entered into a strategic collaboration with Evotec AG for the discovery and development of novel treatments for multiple serious viral infectious diseases. |
Competitor Comparison
| Key Parameters | Abivax SA | Valneva SE | GenSight Biologics SA | Acticor Biotech SAS | Invectys SA |
|---|---|---|---|---|---|
| Headquarters | France | France | France | France | France |
| City | Paris | Lyon | Paris | Paris | Paris |
| State/Province | Ile-de-France | Lorraine | Ile-de-France | - | Ile-de-France |
| No. of Employees | 68 | 674 | 13 | - | - |
| Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Marc de Garidel | Chief Executive Officer; Chairman | Executive Board | 2023 | - |
| Didier Blondel | Secretary; Chief Financial Officer; Executive Vice President | Senior Management | - | - |
| Ida Hatoum | Chief People Officer | Senior Management | 2023 | - |
| Sheldon Sloan, MD | Chief Medical Officer | Senior Management | 2023 | - |
| Didier Scherrer PhD | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer